United Kingdom-Macclesfield: Molecubes Preclinical SPECT Imager
Details
| Contract Title: | United Kingdom-Macclesfield: Molecubes Preclinical SPECT Imager |
| Published Date: | Sep 23, 2025 |
| Notice Type: | Award (ContractAwardNotice) |
| Value Banding: | High Value |
| Delivery Point: | United Kingdom |
Description:
MDC's current imaging capabilities are limited to PET and CT, which restricts us to PET based tracers. While PET imaging is a powerful tool, it cannot accommodate a growing range of radioisotopes that are increasingly relevant in theranostic applications. These include lead 203, lead 212, lutetium 177, and actinium 225, which are essential for both diagnostic and therapeutic purposes. This limitation has become more pronounced as clinical and research interest in SPECT and CT imaging continues ...